Shams ul Nisa

GlaxoSmithKline (GSK) Pakistan saw a strong profit rebound in 1QCY25, driven by CPI-linked pricing and deregulation of non-essential products amid economic pressures, reports WealthPK.

Amid easing inflation and gradual economic stabilization, GSK Pakistan’s adoption of CPI-based pricing and sectoral deregulation has significantly boosted its financial performance. The government’s approval of price adjustments for non-essential medicines enabled the company to raise prices strategically, resulting in a 20% increase in gross margin to 34.2% in 1QCY25. According to the company’s board report, this pricing flexibility has helped GSK manage rising input costs while continuing to invest in innovation and ensuring access to essential medicines. Despite a difficult economic environment marked by slow growth and rising unemployment, GSK Pakistan delivered a strong bottom-line performance in 1QCY25.

However, the net sales remained flat at Rs15.6 billion due to industry-wide stagnation, the company maintained strict cost controls, keeping operating expenses stable relative to sales. This disciplined approach led to a sharp rise in profit after tax from Rs565 million to Rs2.1 billion. Moreover, as of March 31, 2025, the company has earmarked Rs629 million in capital expenditures for plant upgrades, machinery enhancements, and digital transformation, aimed at boosting manufacturing capacity and strengthening the local supply chain.

Alongside these investments, GSK continues to prioritize talent development, innovation, and a collaborative work culture, reinforcing its role in supporting Pakistan’s broader economic and social progress. While GSK Pakistan continues to strengthen its domestic position, it remains alert to global economic uncertainties. Fluctuating foreign capital inflows and evolving US trade policies pose risks that could impact exporters and multinational operations in Pakistan.

The company has acknowledged concerns over potential global downturns but remains confident in its strong business foundations, adaptable market strategy, and the advantages gained from recent regulatory and pricing reforms. Looking ahead, GSK Pakistan has emphasized its commitment to developing human capital as a cornerstone of long-term success. Reforms such as CPI-based pricing and deregulation have played a central role in strengthening GSK Pakistan’s position within a gradually recovering economy.

These changes have supported higher margins, strategic investments, and renewed focus on operations and workforce development, all while navigating both local and global risks. As Pakistan’s healthcare landscape continues to evolve, GSK’s experience illustrates how responsive policies and corporate agility can promote growth, enhance efficiency, and expand access to essential medical innovation.

Credit: INP-WealthPk